Front Page VSPN Message Boards Chat Library Continual Education Search MyVSPN - Coming Soon Help Frequently Asked Questions Send us Feedback! Go to VIN Industry Partners Go to VetQuest Go to Veterinary Partner Go to Y2Spay
 
Menu bar   Go to the VIN.com Portal
 

ABSTRACT OF THE WEEK

Journal of veterinary internal medicine/ American College of Veterinary Internal Medicine
Volume 38 | Issue 4 (2024 Jul-Aug)

Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats.

J Vet Intern Med. 2024 Jul-Aug;38(4):2099 - 2119.
Stijn J M Niessen1, Hans S Kooistra2, Yaiza Forcada3, Charlotte R Bjørnvad4, Balazs Albrecht5, Franziska Roessner6, Esther Herberich7, Carla Kroh8
1 Veterinary Specialist Consultations & VIN Europe, Hilversum, The Netherlands.; 2 Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.; 3 Veterinary Specialist Consultations & VIN Europe, Hilversum, The Netherlands.; 4 Bjørnvad Consultancy, Vedbæk, Denmark.; 5 Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.; 6 Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.; 7 Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.; 8 Boehringer Ingelheim Vetmedica GmbH, Ingelheim am Rhein, Germany.
© 2024 The Author(s). Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.

Abstract

BACKGROUND:Options for treatment of diabetes mellitus in cats are limited to insulin injections and monitoring for hypoglycemia.
HYPOTHESIS:Once daily sodium-glucose cotransporter-2 inhibitor velagliflozin PO is noninferior to insulin injections.
ANIMALS:Client-owned diabetic cats (127 safety; 116 efficacy assessment).
METHODS:Prospective, randomized (1 mg/kg velagliflozin), positive controlled (titrated Caninsulin), open label, noninferiority field trial, comparing number of cats with treatment success in ≥1 clinical variable and ≥1 glycemic variable (margin Δ: 15%) on Day 45; secondary endpoints included glycemic and clinical assessments during 91 days.
RESULTS:On Day 45, 29/54 (54%) velagliflozin-treated cats and 26/62 (42%) Caninsulin-treated cats showed treatment success, demonstrating noninferiority (difference -11.8%; upper 1-sided 97.5% confidence interval, -∞ to 6.3%). By Day 91, quality of life (QoL), polyuria, and polydipsia had improved in 81%, 54% and 61% (velagliflozin); on blood glucose (BG) curves, mean BG was <252 mg/dL in 42/54 (78%; velagliflozin) and 37/62 (60%; Caninsulin); minimum BG was <162 mg/dL in 41/54 (76%; velagliflozin) and 41/62 (66%; Caninsulin); serum fructosamine was <450 μmol/L in 41/54 (76%; velagliflozin) and 38/62 (61%; Caninsulin). Velagliflozin's most frequent adverse events were loose feces/diarrhea (n = 23/61, 38%), positive urine culture (n = 19/61, 31%), and nonclinical hypoglycemia (BG <63 mg/dL; n = 8/61, 13%); Caninsulin's: clinical and nonclinical hypoglycemia (n = 35/66, 53%), positive urine culture (n = 18/66, 27%), and loose feces/diarrhea (n = 10/66, 15%). Diabetic ketoacidosis occurred in 4/61 (7%; velagliflozin) and 0/66 (Caninsulin).
CONCLUSIONS AND CLINICAL IMPORTANCE:Once daily oral administration of velagliflozin was noninferior to insulin injections, showed good QoL and glycemia without clinical hypoglycemia.

Keywords
antidiabetic; beta‐cell; compliance; feline diabetes mellitus; glucosuria; glucotoxicity; glycemic control; prospective clinical trial; sodium‐glucose cotransporter‐2 (SGLT2) inhibitor;

Article Tools:
   Medline
   Email to me

Grants:
Boehringer Ingelheim Animal Health

Archives Highlights:
Emergency Approach to Acute Seizures in Dogs and Cats.
This review presents a systematic approach to the diagnosis and treatment of single seizures, cluster seizures, and status epilepticus in dogs and cats.
Performing an Avian Physical Examination in Practice
As with mammalian physical examinations, it is important to develop a consistent order for the avian examination to thoroughly evaluate each body system. Some components of the physical examination differ between avian species. For example, cloacal palpation is performed in chickens, but not in parrots.
Companion animal veterinary personnel have occupational risk for tularemia and One Health role for tularemia prevention in Kansas.
Forty-three percent (47 of 109) of veterinarians reported diagnosing tularemia in cats and 13% (14 of 109) in dogs. Seven percent (8 of 109) of veterinarians reported having had tularemia. When performing procedures with a high risk of exposure, such as lancing abscesses in tularemia suspects, glove use was 100% but additional personal protective equipment was inconsistent, including eye protection (70%) and surgical face mask (59%).
Investigating the Reasons behind Companion Animal Relinquishment: A Systematic Content Analysis of Shelter Records for Cats and Dogs, 2018-2023.
The most frequent reasons cited were Behavior Issues (28%), Housing/Moving (18%), Unable to Care (16%), Too Many Pets (10%), Financial (6%), and Owner Allergies (5%). The most common behavioral reasons reported were Aggression (32% of behavioral surrenders), Social Conflict (28%), and Soiling (13%).
Case series of maggot debridement therapy demonstrates safety and efficacy for treating problematic wounds in cats and dogs in Mexico.
Treatment was administered by applying 8-10 larvae per square cm surface area directly on the wound bed and covering the wound with a sterile polyester mesh, sutured to the skin. These were left on the wound for cycles of approximately 48 hours (24-72 hours); the cycles were repeated if more than 20% necrotic tissue remained after treatment. Review of these cases revealed that 80% of treated wounds achieved 100% debridement within 48-96 hours of treatment.

Back Print Save Bookmark in my Browser Email this article to me. Top of Page. VSPN AOW : Efficacy and safety of on...
Contact Us